NASDAQ · CGC
Healthcare · Drug Manufacturers - Specialty & Generic
$0.92
Down-$0.00 (-0.49%)
Updated Sep 17, 2026, 9:22 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CGC closed at $0.92 after 20 trading sessions, down 11.96% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $0.92 | $0.9298 | $0.9151 | $0.9156 | 1.33M |
| Sep 15, 2026 | $0.945 | $0.95 | $0.9146 | $0.9201 | 1.57M |
| Sep 14, 2026 | $0.9324 | $0.9545 | $0.92 | $0.9384 | 2.1M |
| Sep 11, 2026 | $0.944 | $0.95 | $0.9157 | $0.9277 | 2.33M |
| Sep 10, 2026 | $0.9488 | $0.9542 | $0.922 | $0.93 | 2.99M |
| Sep 9, 2026 | $0.9655 | $0.9698 | $0.9532 | $0.9594 | 2.27M |
| Sep 8, 2026 | $0.9711 | $0.9976 | $0.9569 | $0.9655 | 2.23M |
| Sep 4, 2026 | $0.9793 | $0.9793 | $0.96 | $0.9727 | 1.9M |
| Sep 3, 2026 | $0.979 | $0.99 | $0.9608 | $0.9729 | 1.71M |
| Sep 2, 2026 | $0.9775 | $0.9936 | $0.9643 | $0.9681 | 1.89M |
| Sep 1, 2026 | $0.9899 | $0.9997 | $0.9659 | $0.9751 | 2.42M |
| Aug 31, 2026 | $0.9938 | $1.01 | $0.9841 | $0.995 | 1.85M |
| Aug 28, 2026 | $1.01 | $1.015 | $0.98 | $0.9995 | 3.84M |
| Aug 27, 2026 | $1.03 | $1.04 | $1.00 | $1.01 | 3.06M |
| Aug 26, 2026 | $1.06 | $1.07 | $1.03 | $1.035 | 2.65M |
| Aug 25, 2026 | $1.06 | $1.08 | $1.045 | $1.07 | 3.14M |
| Aug 24, 2026 | $1.05 | $1.075 | $1.04 | $1.05 | 4.13M |
| Aug 21, 2026 | $1.05 | $1.08 | $1.05 | $1.05 | 5.42M |
| Aug 20, 2026 | $1.04 | $1.06 | $1.01 | $1.05 | 9.01M |
| Aug 19, 2026 | $0.99 | $1.05 | $0.9885 | $1.04 | 7.32M |
The latest Smart Investors Daily articles mentioning CGC.
CGC research
Company profile and research snapshot.
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 15, 2026 | ROTH CAPITAL PARTNERS | Buy | — |
| Jun 15, 2026 | ALLIANCE GLOBAL PARTNERS | Neutral | — |
| Jun 14, 2026 | CANACCORD GENUITY | Buy | — |
| Feb 8, 2026 | ATB CAPITAL MARKETS | Underperform | — |
| Dec 16, 2025 | ROTH CAPITAL PARTNERS | Buy | — |
No generated briefing is available yet.
Benzinga · Feb 18, 2026
Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) is pleased to announce that shareholders of MTL Cannabis Corp. ("MTL Cannabis" or "MTL") have voted to approve the Company's previously
Yahoo · Feb 12, 2026
The cannabis company's shares have plummeted by more than 40% over the past year.
Benzinga · Feb 12, 2026
Yahoo · Feb 11, 2026
CGC beats Q3 estimates as Canadian cannabis sales rise, but margin pressure and global volatility cloud its path to sustained profitability.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CGC.
